AnaptysBio ends UC trial, advances RA program, plans 2026 split
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
Alector announces 49% workforce reduction and discontinuation of latozinemab trials after Phase 3 study fails to show clinical benefit in frontotemporal dementia patients.
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.